Hekimian Guillaume, Kharcha Fatima, Bréchot Nicolas, Schmidt Matthieu, Ghander Cécile, Lebreton Guillaume, Girerd Xavier, Tresallet Christophe, Trouillet Jean-Louis, Leprince Pascal, Chastre Jean, Combes Alain, Luyt Charles-Edouard
Intensive Care Unit, Institute of Cardiology, Groupe Hospitalier Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris, Paris, France.
UPMC Université Paris 06, INSERM, UMRS_1166-ICAN Institute of Cardiometabolism and Nutrition, Paris, France.
Ann Intensive Care. 2016 Dec;6(1):117. doi: 10.1186/s13613-016-0219-4. Epub 2016 Nov 28.
Pheochromocytoma, a rare catecholamine-producing tumor, might provoke stress-induced Takotsubo-like cardiomyopathy and severe cardiogenic shock. Because venoarterial-extracorporeal membrane oxygenation (VA-ECMO) rescue of pheochromocytoma-induced refractory cardiogenic shock has rarely been reported, we reviewed our ICU patients' presentations and outcomes.
All pheochromocytoma-induced refractory cardiogenic shock cases managed with VA-ECMO (January 2007-March 2015) were prospectively included and reviewed. We also performed a systematic review on this topic.
Nine patients (7 women, 2 men; 31-51 [median, 43 (IQR 36-49) years old]) were included; none had a previously known pheochromocytoma. Six of them had medical histories suggestive of the diagnosis: palpitations and headaches for several months for four, multiple endocrine neoplasia syndrome type 1 for one and recurrent Takotsubo disease for one; at hospital admission, all were hypertensive despite cardiogenic shock. Three others had an identified surgical triggering factor. All nine patients rapidly developed refractory cardiogenic shock with very severe left ventricular (LV) impairment (LV ejection-fraction range 5-20%; LV outflow-tract velocity-time integral range 3-8 cm). Seven patients' abdominal computed tomography scans showed pheochromocytoma-suggestive adrenal gland tumors (no scan during ICU stay for 2). Despite VA-ECMO implantation, three patients died of refractory multiple organ failure. For the six others, myocardial function improved and ECMO was removed 3-7 days post-implantation; α- and β-blockers were progressively introduced. Five survivors underwent pheochromocytoma excision 3 weeks-4 months post-ICU discharge, with satisfactory outcomes. One patient, whose pheochromocytoma was diagnosed 1 year after the index event, underwent uneventful surgical adrenalectomy. Systematic review retrieved 40 cases of pheochromocytoma-induced cardiogenic shock requiring mechanical support (mostly ECMO), with a mortality rate of 7%. Pheochromocytoma was removed surgically after mechanical support weaning in 31 patients and during mechanical support in 5. Four were not operated.
Pheochromocytoma is a rare but reversible cause of cardiogenic shock amenable to VA-ECMO rescue. Adrenal gland imaging should be obtained for all patients with unexplained cardiogenic shock. Lastly, it might be safer to perform adrenalectomy several weeks after the initial catastrophic presentation, once recovery of LV systolic function is complete.
嗜铬细胞瘤是一种罕见的分泌儿茶酚胺的肿瘤,可能引发应激性Takotsubo样心肌病和严重的心源性休克。由于关于嗜铬细胞瘤所致难治性心源性休克采用静脉-动脉体外膜肺氧合(VA-ECMO)抢救的报道很少,我们回顾了我们重症监护病房(ICU)患者的临床表现和治疗结果。
前瞻性纳入并回顾了2007年1月至2015年3月期间所有采用VA-ECMO治疗的嗜铬细胞瘤所致难治性心源性休克病例。我们还对该主题进行了系统综述。
纳入9例患者(7例女性,2例男性;年龄31 - 51岁[中位数43岁(四分位间距36 - 49岁)]);均无既往已知的嗜铬细胞瘤。其中6例有提示诊断的病史:4例有数月的心悸和头痛,1例有1型多发性内分泌肿瘤综合征,1例有复发性Takotsubo病;入院时,尽管有心源性休克,但所有患者均为高血压。另外3例有明确的手术诱发因素。所有9例患者均迅速发展为难治性心源性休克,伴有非常严重的左心室(LV)功能损害(LV射血分数范围为5% - 20%;LV流出道速度时间积分范围为3 - 8 cm)。7例患者的腹部计算机断层扫描显示有提示嗜铬细胞瘤的肾上腺肿瘤(2例在ICU住院期间未进行扫描)。尽管植入了VA-ECMO,3例患者死于难治性多器官功能衰竭。对于另外6例患者,心肌功能改善,VA-ECMO在植入后3 - 7天撤除;逐渐加用α和β受体阻滞剂。5例幸存者在ICU出院后3周 - 4个月接受了嗜铬细胞瘤切除术,结果满意。1例患者在索引事件发生1年后诊断出嗜铬细胞瘤,接受了顺利的肾上腺切除术。系统综述检索到40例嗜铬细胞瘤所致心源性休克需要机械支持(主要是ECMO)的病例,死亡率为7%。31例患者在机械支持撤机后接受了手术切除嗜铬细胞瘤,5例在机械支持期间接受了手术切除。4例未进行手术。
嗜铬细胞瘤是心源性休克的一种罕见但可逆的病因,适合采用VA-ECMO抢救。对于所有不明原因的心源性休克患者均应进行肾上腺成像检查。最后,在最初灾难性表现数周后,一旦LV收缩功能完全恢复,进行肾上腺切除术可能更安全。